Last updated: August 28, 2026
Apomorphine hydrochloride is a mature, specialized Parkinson's disease rescue therapy with limited volume, high clinical value in advanced disease, and uneven commercial performance. The U.S. market is centered on Apokyn injection, marketed by Supernus Pharmaceuticals after its acquisition of U.S. WorldMeds assets. Kynmobi, a sublingual film launched by Sunovion in 2020, was later discontinued in the United States. Outside the U.S., apomorphine is used in intermittent injections and continuous subcutaneous infusion products, including APO-go and Dacepton.
The commercial outlook is stable to modestly positive for injectable rescue therapy but constrained by administration burden, reimbursement, device complexity, and competition from inhaled levodopa and newer continuous dopaminergic therapies. Apomorphine hydrochloride is a small molecule, so biosimilar risk does not apply. Generic risk is more relevant, particularly for simple injectable presentations, although delivery devices, formulation, training, and regulatory requirements raise entry barriers.
What is the current market position of apomorphine hydrochloride?
Apomorphine hydrochloride occupies a narrow segment of the Parkinson's disease market. It is used primarily for acute treatment of "off" episodes, when patients with advanced Parkinson's disease experience a sudden loss of levodopa benefit.
| Product or format |
Market status |
Primary use |
Commercial relevance |
| Apokyn injection |
U.S. marketed product |
Acute treatment of off episodes |
Core U.S. franchise |
| Kynmobi sublingual film |
U.S. commercial availability discontinued |
Acute treatment of off episodes |
No current U.S. growth platform |
| APO-go injection and infusion |
Marketed in multiple non-U.S. markets |
Rescue dosing and continuous infusion |
Important European presence |
| Dacepton injection and infusion |
Marketed in selected countries |
Advanced Parkinson's disease |
Regional competitor |
| Compounded apomorphine |
Available in limited settings |
Off-label or specialist use |
Price and quality vary by jurisdiction |
Apomorphine is a dopamine agonist with rapid onset. It is not a disease-modifying therapy and does not replace levodopa. Its value is concentrated in patients whose oral treatment regimen no longer provides predictable motor control.
The market is therefore driven by the prevalence of advanced Parkinson's disease, diagnosis and referral to movement-disorder specialists, payer coverage, caregiver support, and the availability of infusion or injection services.
How large is the apomorphine hydrochloride market?
Public companies generally do not disclose a standalone global apomorphine hydrochloride market figure. Reported sales are fragmented across product formats, countries, subsidiaries, and broader neurology portfolios.
The addressable population is a small subset of the global Parkinson's disease population. Parkinson's disease affects millions of people worldwide, but only a minority develops frequent, clinically significant off episodes and receives apomorphine therapy. Treatment adoption is limited by nausea, hypotension, somnolence, impulse-control concerns, injection-site reactions, and the need for supervised dose initiation.
Commercial market characteristics include:
- Low patient volume compared with oral levodopa products.
- High revenue per treated patient in branded markets.
- Specialist prescribing and concentrated distribution.
- Significant dependence on reimbursement and prior authorization.
- Limited substitution between intermittent rescue and continuous infusion products.
- Higher technical barriers for pen injectors, cartridges, and infusion systems than for ordinary injectable ampoules.
European markets are generally more familiar with continuous subcutaneous apomorphine infusion. The U.S. market has historically favored intermittent rescue treatment through Apokyn, although newer continuous therapies increase competitive pressure.
What is the financial trajectory for apomorphine hydrochloride products?
The financial trajectory is best characterized as mature and concentrated rather than high growth. U.S. revenue has shifted from an independent-company product to a portfolio asset within Supernus Pharmaceuticals. Supernus acquired U.S. WorldMeds' commercial products, including Apokyn, in 2022. The transaction expanded Supernus' Parkinson's disease portfolio but also added products with mature-market characteristics and specialized commercial infrastructure.
Supernus reports consolidated product revenue rather than presenting a complete global apomorphine market income statement. Public filings indicate that Apokyn contributes recurring revenue, but the product is not large enough to determine Supernus' overall financial trajectory. Supernus' larger products and pipeline assets remain more important to total corporate valuation and operating leverage.[1]
Key financial drivers
Revenue is supported by:
- Continued use in advanced Parkinson's disease.
- High treatment value for rapid rescue of off episodes.
- Specialist familiarity with Apokyn.
- Limited direct substitutes with identical rapid-response positioning.
- Potential expansion of continuous infusion use outside the United States.
Revenue is constrained by:
- A small eligible population.
- Product discontinuation of Kynmobi in the United States.
- Administration complexity.
- Payer restrictions and high patient out-of-pocket exposure.
- Competition from Inbrija, Vyalev, levodopa optimization, and device-aided therapies.
- Potential generic or authorized-generic pressure on injectable formats.
The product's margin profile can remain attractive if pricing is maintained, but commercial costs are high. Patient onboarding, injection training, specialty pharmacy operations, reimbursement support, and adverse-event management are more expensive than for standard oral Parkinson's medicines.
When does apomorphine hydrochloride lose exclusivity?
Apomorphine hydrochloride is an old active pharmaceutical ingredient. Its basic chemical composition has long been off patent in major jurisdictions. Commercial protection therefore depends on product-specific patents, formulation claims, delivery devices, regulatory exclusivity, trademarks, manufacturing know-how, and market access execution.
The principal U.S. branded product is Apokyn, approved under NDA 020799. The FDA's Orange Book is the controlling source for listed patents and regulatory exclusivity associated with the approved product.[2]
| Protection category |
Apomorphine hydrochloride position |
| Active ingredient patent |
Generally expired or unavailable because the molecule is old |
| Product formulation |
May be protected through product-specific claims, but protection is limited by product age |
| Injection device |
Possible device and design protection |
| Sublingual film |
Product-specific protection applied to Kynmobi, but U.S. commercial status ended |
| Method of use |
Possible claims covering treatment of Parkinson's off episodes |
| Regulatory exclusivity |
Historical exclusivity periods have expired for the early U.S. products |
| Trade secrets |
Dose titration, manufacturing, device supply, and patient-support processes may remain commercially relevant |
The practical loss-of-exclusivity question is not limited to the expiry of one patent. A generic competitor must obtain approval for the same dosage form, demonstrate pharmaceutical equivalence, address device requirements, and compete against a branded product with established reimbursement and support programs.
What is the Orange Book status of Apokyn?
Apokyn is an FDA-approved apomorphine hydrochloride injection product for acute treatment of hypomobility and "off" episodes in patients with Parkinson's disease. The Orange Book should be used to confirm current patent listings, delisting events, and the status of any approved abbreviated new drug applications.[2]
Apokyn's regulatory position is stronger than its active-ingredient patent position because the product has a recognized FDA label, established clinical use, and a specialized administration process. Its protection is therefore commercial and regulatory as much as chemical.
The key Orange Book risks are:
- Listed patents covering formulation, dosing, device, or use.
- Paragraph IV certifications from generic applicants.
- Patent delisting or expiration that changes the timing of generic entry.
- Whether a generic applicant can reproduce the injector or cartridge system.
- Whether a competing product uses a different delivery system and avoids listed claims.
No biosimilar pathway applies. Apomorphine hydrochloride is a chemically synthesized small molecule and would be regulated as a generic drug, not as a biosimilar biologic.
Which companies are challenging the apomorphine hydrochloride market?
Competitive pressure comes from therapies that reduce the need for rescue injections rather than from a large number of direct apomorphine competitors.
Inbrija
Inbrija is inhaled levodopa, marketed by Acorda Therapeutics. It treats intermittent off episodes and competes directly with Apokyn for rapid, on-demand treatment. Inbrija avoids injection but requires inhalation capability and has its own device and pulmonary-use limitations.[3]
Vyalev
Vyalev, approved by the FDA in 2024, is a continuous subcutaneous infusion of foslevodopa and foscarbidopa for motor fluctuations in advanced Parkinson's disease. It competes with continuous apomorphine infusion in patients who need device-aided treatment throughout the day.[4]
Levodopa-carbidopa intestinal gel
Continuous intestinal infusion products compete for patients with severe motor fluctuations. Their procedural and device burden differs from apomorphine infusion, but the clinical target population overlaps.
Oral and transdermal dopamine therapies
Extended-release levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and transdermal rotigotine can delay or reduce rescue-therapy use in some patients. These products usually do not provide the same rapid reversal of an established off episode.
How does apomorphine compare with competing Parkinson's rescue therapies?
| Attribute |
Apomorphine injection |
Inbrija |
Vyalev |
Oral rescue or optimization |
| Active therapy |
Dopamine agonist |
Levodopa |
Foslevodopa/foscarbidopa |
Varies |
| Administration |
Subcutaneous injection |
Inhalation |
Continuous subcutaneous infusion |
Oral or transdermal |
| Main role |
Rapid rescue |
Rapid rescue |
Continuous control |
Background optimization |
| Onset |
Rapid |
Rapid |
Continuous delivery |
Usually slower or variable |
| Patient burden |
Injection and titration |
Inhaler technique |
Pump or infusion system |
Lower |
| Target population |
Advanced PD with off episodes |
PD with off episodes |
Advanced PD with motor fluctuations |
Broad PD population |
| Direct generic risk |
Possible |
Product and device dependent |
Low near term |
Higher for older oral products |
Apomorphine retains a clinical niche because it can rapidly restore mobility when oral levodopa is unreliable. Its disadvantage is that the same rapid pharmacology requires a more demanding delivery method.
What formulations are protected by apomorphine hydrochloride products?
The commercial value of apomorphine hydrochloride depends heavily on formulation and delivery technology.
Injectable formulations
Injectable products may use multidose pens, cartridges, prefilled systems, or vials. Device patents, dose-delivery mechanisms, cartridge compatibility, and human-factors evidence can delay a generic even when the active ingredient is old.
Sublingual film
Kynmobi used a sublingual film designed to deliver apomorphine without injection. The product addressed injection aversion but faced tolerability, commercial, and competitive challenges. Sunovion discontinued U.S. commercial availability, removing the principal branded non-injectable apomorphine platform from that market.[5]
Continuous infusion
Continuous subcutaneous infusion relies on pump compatibility, infusion-site management, concentration, stability, and patient-support services. These factors create manufacturing and operational barriers that are not present in a standard vial product.
What is the FDA regulatory status of apomorphine hydrochloride?
Apokyn remains an FDA-approved product for acute treatment of off episodes associated with Parkinson's disease. The FDA-approved label includes dose initiation and titration requirements, reflecting the risk of hypotension, nausea, vomiting, somnolence, dyskinesia, and other dopamine-agonist effects.[6]
The most important regulatory characteristics are:
- Prescription-only use.
- Specialist initiation and titration.
- Need for careful patient selection.
- Formulation-specific approval.
- No interchangeability across injection, film, and infusion products without separate regulatory approval.
- Generic approval under an ANDA pathway for qualifying injectable products.
FDA approval does not guarantee broad coverage. Payers can impose step therapy, prior authorization, specialty-pharmacy requirements, and restrictions tied to disease severity.
What patent litigation and Paragraph IV risks affect apomorphine?
Publicly visible litigation risk is lower than for newer blockbuster products because the principal apomorphine molecule is old and the market is small. The principal legal risk would arise if a generic applicant filed a Paragraph IV certification against unexpired Apokyn patents listed in the Orange Book.
Potential dispute areas include:
- Injector or cartridge design.
- Concentration and excipient composition.
- Dosing regimens.
- Treatment of off episodes.
- Method-of-use claims.
- Stability and container-closure systems.
- Pharmaceutical equivalence and device performance.
A generic entrant could also pursue a section viii statement and omit patented methods of use, depending on the scope of listed claims. That strategy could reduce litigation exposure but may narrow the approved label.
The litigation economics are important. A patent suit may be less attractive to the brand owner if expected annual sales are modest, while a generic company may avoid entry if device-development costs are high relative to the addressable market.
What generic launch scenarios exist for apomorphine hydrochloride?
Three scenarios are commercially plausible.
Scenario 1: No near-term generic launch
The branded product remains protected by listed claims, device complexity, or limited market attractiveness. Supernus maintains pricing and uses patient-support programs to defend share.
Scenario 2: One injectable generic entrant
A single ANDA-approved competitor enters after patent expiry or settlement. The entrant targets the simplest injectable presentation and discounts selectively. Net pricing declines, but the brand retains patients who value established device support.
Scenario 3: Multiple entrants and rapid erosion
Several manufacturers enter a conventional injectable product. Payers shift utilization toward lower-cost products, specialty distribution weakens, and branded revenue falls rapidly. This scenario is more likely if the market lacks meaningful device or formulation protection.
A generic launch would not necessarily eliminate branded apomorphine. Patients and physicians may remain sensitive to injector usability, titration support, supply continuity, and reimbursement.
How strong is the apomorphine hydrochloride patent estate?
The estate is moderate to weak at the active-ingredient level and stronger at the product-delivery level.
| Estate component |
Relative strength |
Reason |
| Apomorphine molecule |
Weak |
Old, well-known active ingredient |
| Basic injection composition |
Weak to moderate |
Potentially vulnerable to prior art |
| Pen or cartridge system |
Moderate |
Device engineering may create narrower claims |
| Sublingual film |
Product-specific |
Kynmobi commercial discontinuation reduces value |
| Continuous infusion |
Moderate |
Pump, concentration, stability, and use claims may matter |
| Manufacturing process |
Moderate |
Can create barriers but may not block a competing product |
| Method of use |
Variable |
Claim scope and prior art determine enforceability |
The estate should be evaluated as a platform of narrower rights rather than as a single blocking patent. The strongest commercial barrier may be accumulated operational know-how rather than broad exclusivity.
What licensing deals affect apomorphine hydrochloride?
The most relevant transaction is Supernus Pharmaceuticals' acquisition of U.S. WorldMeds' commercial products in 2022. The transaction included Apokyn and other neurology products and transferred commercial responsibility for the U.S. franchise to Supernus.[1]
International rights are more fragmented. APO-go and related products are associated with Britannia Pharmaceuticals, while other regional products and infusion systems are commercialized through country-specific arrangements. This creates a geographically segmented market with different prices, reimbursement systems, patent positions, and manufacturing relationships.
Licensing value is limited by the product's niche size. A potential transaction would be more attractive if it included:
- Established specialty distribution.
- Pump or injector technology.
- Reimbursement infrastructure.
- Rights across several major markets.
- Manufacturing capacity for sterile injectable products.
- Data supporting continuous infusion or expanded use.
What geographic markets offer the strongest opportunity?
Europe has the deepest established use of continuous apomorphine infusion. The United Kingdom and selected Western European markets have specialist infrastructure and clinical familiarity with device-aided Parkinson's treatment.
The United States offers higher branded pricing but has a narrower commercial model centered on intermittent rescue injection. Access depends heavily on insurance coverage and specialty-pharmacy execution.
Emerging markets may have clinical demand but face constraints from product price, cold-chain or sterile manufacturing requirements, specialist availability, and reimbursement. Local injectable competitors can create price pressure, but regulatory and quality requirements remain important barriers.
What manufacturing and intellectual-property barriers exist?
Apomorphine hydrochloride manufacturing is more demanding than production of a conventional oral tablet. Key issues include:
- Sterile fill-finish capability.
- Control of oxidation and degradation.
- Container-closure compatibility.
- Stability of the solution.
- Reliable cartridge and injector supply.
- Dose accuracy at low volumes.
- Device assembly and human-factors testing.
- Specialized packaging and distribution.
- Pharmacovigilance for a high-risk movement-disorder population.
For continuous infusion, manufacturers must also manage pump compatibility, infusion-site performance, product concentration, and patient training. These factors can limit the number of credible suppliers even after basic patent barriers decline.
What is the revenue exposure for manufacturers?
Apomorphine revenue exposure is concentrated in a small number of companies and is material at the product level but generally modest at the diversified-company level.
- Supernus has direct U.S. exposure through Apokyn.
- Britannia Pharmaceuticals has exposure to APO-go and related apomorphine products in international markets.
- Sunovion no longer has a continuing U.S. Kynmobi growth platform after discontinuation.
- Generic manufacturers could enter selectively if they can support sterile production and device requirements.
- Pump and delivery-system suppliers may capture value even when drug pricing declines.
The principal valuation risk is revenue erosion from generic injectable entry or loss of reimbursement. The principal upside is greater adoption of rescue therapy and continuous infusion in patients with advanced motor fluctuations.
Key Takeaways
- Apomorphine hydrochloride is a mature, niche Parkinson's disease product with high clinical utility but limited volume.
- Apokyn injection is the core U.S. commercial product and is marketed by Supernus.
- Kynmobi sublingual film was discontinued in U.S. commercial use, reducing non-injectable competition within the apomorphine class.
- The molecule has little meaningful active-ingredient patent protection; commercial barriers are concentrated in devices, formulations, manufacturing, and specialist support.
- Biosimilar risk does not apply because apomorphine hydrochloride is a small molecule.
- Generic injectable entry is the principal long-term exclusivity risk.
- Vyalev and Inbrija are important competitive products, although they address the disease through different delivery systems.
- European markets offer stronger infrastructure for continuous apomorphine infusion than the United States.
- Financial performance is likely to remain stable or modestly positive while branded access is maintained, followed by sharper erosion if multiple generic injectables enter.
FAQs
Is apomorphine hydrochloride a generic drug?
Apomorphine hydrochloride is an old small-molecule active ingredient, but branded products such as Apokyn are approved prescription medicines. Generic status depends on the specific product, dosage form, device, and ANDA approval.
Is apomorphine hydrochloride available as an infusion?
Yes. Continuous subcutaneous apomorphine infusion products are used in several international markets for advanced Parkinson's disease with persistent motor fluctuations.
Does Medicare cover Apokyn?
Coverage depends on the patient's Medicare benefit, plan rules, prior authorization requirements, and specialty-pharmacy arrangements. Coverage is not uniform across Medicare plans.
Can apomorphine hydrochloride be compounded?
Compounded apomorphine may be available in limited jurisdictions and clinical settings, but compounded products are not equivalent to an FDA-approved branded or generic product in regulatory status, manufacturing controls, or labeling.
What drug is most likely to replace apomorphine hydrochloride?
No single product is a complete replacement. Inbrija competes for rapid rescue, while Vyalev and other device-aided therapies compete for continuous control of advanced motor fluctuations.
References
-
Supernus Pharmaceuticals, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
U.S. Food and Drug Administration. (2018). Inbrija (levodopa inhalation powder) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Vyalev (foscarbidopa and foslevodopa) prescribing information. FDA.
-
Sunovion Pharmaceuticals Inc. (2023). Kynmobi commercial availability update. Sunovion Pharmaceuticals.
-
U.S. Food and Drug Administration. (2024). Apokyn (apomorphine hydrochloride injection) prescribing information. FDA.
